Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin

Author:

Gan Kennard,Li Zhuoxuan,Darli Phyo Maw,Wong Teresa,Modh Harshvardhan,Gottier Petra,Halbherr Stéfan,Wacker Matthias G.

Funder

NRF

Publisher

Elsevier BV

Reference35 articles.

1. The Liposomal Formulation of Doxorubicin;Abraham;Methods Enzymol,2005

2. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer;Bagheri;Life Sci,2020

3. Doxil® — The first FDA-approved nano-drug: Lessons learned;Barenholz;J Control Release,2012

4. Doxil® – the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical Use;Barenholz,2016

5. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy;Batist;Expert Opin Pharmacother,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3